Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sees Large Volume Increase - Here's What Happened

Key Points

• Hikma Pharmaceuticals experienced a significant increase in trading volume, with approximately 7,007 shares traded, representing a 342% rise from the prior session's volume.
• BNP Paribas has initiated coverage with an "outperform" rating, while the consensus rating for Hikma Pharmaceuticals is currently a "Buy."
• The stock is currently trading at $22.80, down 3.1% from its last close at $23.41, indicating some recent volatility in its market performance.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares saw an uptick in trading volume on Wednesday . 7,007 shares were traded during mid-day trading, an increase of 342% from the previous session's volume of 1,584 shares.The stock last traded at $22.80 and had previously closed at $23.41.

Hikma Pharmaceuticals Price Performance

The stock has a fifty day simple moving average of $25.70 and a 200-day simple moving average of $26.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.24 and a quick ratio of 0.72.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.